Acalabrutinib (Calquence®) is accepted for restricted use within NHSScotland for untreated chronic lymphocytic leukaemia

Use as monotherapy is restricted for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia who have a 17p deletion or TP53 mutation and in whom chemo-immunotherapy is unsuitable.

Source:

Scottish Medicines Consortium